Christopher Laudani is the founder and president of, a short-only equity research firm.

The toolmaker's acquisition of the Craftsman brand should help push its profits and share price up in 2017.
It's time to ride this beast higher based on its strong top- and bottom-line momentum.
The company is the leading maker of transcatheter arterial heart valve replacements.
Fiscal 2017 revenue should increase at least 8%.
For some reason, competition or wrong product mix, it doesn't grow that fast.
This week's introduction of the NovaSeq Series of genomic sequencers caused the stock to jump.
The company's share price still has potential upside.
The company has made substantial changes and should be able to add margin.
ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?
I think ACIA's share price can reach $100 by summer.

Columnist Conversations

Foot Locker's (FL) less than expected quarterly earnings set off a round of selling the entire athletic appare...
View Chart »  View in New Window » Gold has met the first upside target off the last setup zon...
View Chart »  View in New Window »
View Chart »  View in New Window »


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.